Search

Your search keyword '"Yang, Hongqiu"' showing total 163 results

Search Constraints

Start Over You searched for: Author "Yang, Hongqiu" Remove constraint Author: "Yang, Hongqiu"
163 results on '"Yang, Hongqiu"'

Search Results

1. Using latent profile analyses to classify subjects with anhedonia based on reward-related measures obtained in the FAST-MAS study

2. Selective kappa-opioid antagonism ameliorates anhedonic behavior: evidence from the Fast-fail Trial in Mood and Anxiety Spectrum Disorders (FAST-MAS)

3. A randomized proof-of-mechanism trial applying the ‘fast-fail’ approach to evaluating κ-opioid antagonism as a treatment for anhedonia

4. Design and pilot test of an implicit bias mitigation curriculum for clinicians

5. MP78-19 CHARACTERIZING PAIN LOCATION AND INTENSITY FOLLOWING URETEROSCOPY FOR STONES—RESULTS FROM THE USDRN STUDY TO ENHANCE UNDERSTANDING OF STENT-ASSOCIATED SYMPTOMS (STENTS)

8. Mobile Application–Based Communication Facilitation Platform for Family Members of Critically Ill Patients

9. Correction to: Selective kappa-opioid antagonism ameliorates anhedonic behavior: evidence from the Fast-fail Trial in Mood and Anxiety Spectrum Disorders (FAST-MAS)

11. PD34-03 PRE-OPERATIVE CENTRAL SENSITIZATION AND HYPERSENSITIVITY TO PAIN IS ASSOCIATED WITH URETERAL STENT PAIN: FINDINGS FROM THE URINARY STONE DISEASE RESEARCH NETWORK (USDRN)

12. PD34-04 PREDICTIVE MODELS FOR SEVERE PAIN AND URINARY SYMPTOMS AFTER URETEROSCOPY WITH URETERAL STENT PLACEMENT FROM THE USDRN STENTS STUDY

14. Risk Factors for Increased Stent-Associated Symptoms Following Ureteroscopy for Urinary Stones: Results from STENTS

15. Under-reporting and Poor Adherence to Monitoring Guidelines for Severe Cases of Isoniazid Hepatotoxicity

19. Highly Specialized Carbohydrate Metabolism Capability in Bifidobacterium Strains Associated with Intestinal Barrier Maturation in Early Preterm Infants

20. LBA02-08 RISK FACTORS FOR INCREASED STENT-ASSOCIATED SYMPTOMS FOLLOWING URETEROSCOPY FOR URINARY STONES: RESULTS FROM THE URINARY STONE DISEASE RESEARCH NETWORK (USDRN) STENTS STUDY

21. PD50-07 DEFINING STONE PASSAGE IN A CLINICAL TRIAL: ADJUDICATION IN THE PREVENTION OF URINARY STONES WITH HYDRATION (PUSH) STUDY

22. Additional file 2 of Insight into the ecology of vaginal bacteria through integrative analyses of metagenomic and metatranscriptomic data

31. Improving racial disparities in unmet palliative care needs among intensive care unit family members with a needs-targeted app intervention: The ICUconnect randomized clinical trial

34. Apixaban versus warfarin in patients with atrial fibrillation according to prior warfarin use: Results from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial

37. African Americans With Advanced Heart Failure Are More Likely to Die in a Health Care Facility Than at Home or in Hospice: An Analysis From the PAL-HF Trial

38. Ultrahigh-Throughput Multiplexing and Sequencing of >500-Base-Pair Amplicon Regions on the Illumina HiSeq 2500 Platform

40. Role of autophagy in skin photoaging: A narrative review

41. Palliative care and hospital readmissions in patients with advanced heart failure: Insights from the PAL-HF trial

42. Ultra-high throughput multiplexing and sequencing of >500 bp amplicon regions on the Illumina HiSeq 2500 platform

43. Effect of Natriuretic Peptide-Guided Therapy on Outcomes in High-Risk Patients with Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial

44. Effect of Natriuretic Peptide-Guided Therapy on Hospitalization or Cardiovascular Mortality in High-Risk Patients With Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.

45. Effect of Natriuretic Peptide–Guided Therapy on Hospitalization or Cardiovascular Mortality in High-Risk Patients With Heart Failure and Reduced Ejection Fraction

46. Palliative Care in Heart Failure

47. Under-reporting and Poor Adherence to Monitoring Guidelines for Severe Cases of Isoniazid Hepatotoxicity

48. Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation : a secondary analysis of a randomised controlled trial

49. Effect of apixaban, an oral and direct factor Xa inhibitor, on coagulation activity biomarkers following acute coronary syndrome

50. EFFICACY AND SAFETY OF APIXABAN COMPARED WITH WARFARIN ACCORDING TO AGE FOR STROKE PREVENTION IN ATRIAL FIBRILLATION

Catalog

Books, media, physical & digital resources